Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
Open Access
- 25 January 2002
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (1) , 19-25
- https://doi.org/10.1038/sj.bjc.6600002
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- Advanced epithelial ovarian cancer: 1998 consensus statementsAnnals of Oncology, 1999
- Long-term results from a phase II study of single agent paclitaxel (Taxol®) in previously platinum treated patients with advanced ovarian cancer: The Nordic experienceAnnals of Oncology, 1998
- Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1998
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimenEuropean Journal Of Cancer, 1994
- Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1991
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancerGynecologic Oncology, 1987
- Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agentGynecologic Oncology, 1985